<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171468</url>
  </required_header>
  <id_info>
    <org_study_id>1160.61</org_study_id>
    <nct_id>NCT02171468</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects</brief_title>
  <official_title>Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate and compare pharmacokinetics, safety and pharmacodynamics of dabigatran
      etexilate following oral administration of multiple doses (110 mg and 150 mg b.i.d., 7 days)
      in healthy male subjects between Japanese and Caucasians
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in QT(c) intervals</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the concentration-time curve over a uniform dosing interval τ after administration of single dose on Day 1)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum concentration at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (terminal rate constant at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time in the body at steady state after oral administration)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance in the plasma at steady state after extravascular multiple dose administration)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax,13 (accumulation ratio calculated as Cmax,ss/Cmax)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC,13 (accumulation ratio calculated as AUCτ,ss/AUCτ,1)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve for activated partial thromboplastin time (aPTT)</measure>
    <time_frame>0 - 12 hours after adminstration on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve for ecarin clotting time (ECT)</measure>
    <time_frame>0 - 12 hours after adminstration on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of trough concentrations</measure>
    <time_frame>after doses 3, 5, 7, 9, 11 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of trough concentrations morning versus evening</measure>
    <time_frame>after doses 9, 10, 11, 12, 13</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran high dose</intervention_name>
    <arm_group_label>Dabigatran high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran low dose</intervention_name>
    <arm_group_label>Dabigatran low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Japanese or Caucasian healthy male subjects according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure, pulse rate and body temperature), 12-lead electrocardiogram, clinical
             laboratory tests

               -  No finding of clinical relevance

               -  No evidence of a clinically relevant concomitant disease

               -  Caucasian subjects are from a well-defined Caucasian population, both parents of
                  Caucasians, the subjects can understand the subject information for informed
                  consent in English and the subjects have lived 8 or less than 8 years in Japan

          2. Age: ≥20 and ≤45 years

          3. Body mass index (BMI): ≥18.5 and ≤29.9 kg/m2

          4. Signed and dated written informed consent before admission to the trial site

        Exclusion Criteria:

          1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          2. Subject can not use an adequate form of contraception from the time of the first dose
             on Day 1 up to end-of study examination

          3. Current diseases of the central nervous system (such as epilepsy), or psychiatric
             disorders or neurological disorders

          4. History of clinically significant orthostatic hypotension, clinically significant
             current or past fainting spells or blackouts

          5. Chronic or relevant acute infections

          6. History of

               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
                  safety assessment as judged by the investigator (excluding asymptomatic seasonal
                  rhinitis/hay fever)

               -  any bleeding disorder including prolonged or habitual bleeding

               -  other hematologic diseases

               -  cerebral bleeding (e.g. after a car accident)

               -  concussions (head trauma resulting in injuring to brain) with or without loss of
                  consciousness

          7. Intake of drugs with a long half-life (&gt;24 hours) within at least 1 month or less than
             10 half-lives, whichever is shorter, of the respective drug prior to administration or
             during the trial

          8. Use of aspirin (including over-the-counter medications), antipletelet agents like
             ticlopidine or dipyridamole, chronic administration of nonsteroidal antiinflammatory
             drugs , coumadin like anticoagulants, chronic use of corticosteroids, heparin or
             fibrinolytic agents within 28 days prior to administration up to end-of-study
             examination

          9. Participation in another trial with an investigational drug within 3 months prior to
             administration up to end-of-study examination

         10. Smoker (&gt;10 cigarettes/day or inability to refrain from smoking during the trial)

         11. Alcohol abuse (more than 60 g/day; confirmed by interview)

         12. Drug abuse (confirmed by interview)

         13. Blood donation (more than 100 mL from 3 months prior to screening and any blood
             donation from screening up to end-of-study examination)

         14. Excessive physical activities (within 7 days prior to the first drug administration up
             to end-of-study examination)

         15. Any laboratory value outside the reference range that is of clinical relevance

         16. Known hypersensitivity to the investigational drug or its excipients

         17. Subject who was judged ineligible by the investigator or the sub-investigator

         18. History of any familial bleeding disorder

         19. Thrombocytes &lt;15 x 10**4 /microL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

